FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20230515E00154
1. Date of relevant event: 11/05/2023
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 02616
4. Name of listed corporation: CStone Pharmaceuticals - B 
5. Class of shares: Ordinary Shares 
6. Number of issued shares in class: 1,283,867,016
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) Yang
(Other names) Jianxin
10. Name of director (Chinese):  
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1101The number of shares in which you are interested has increased because:
you purchased the shares
 
2101Beneficial owner
 
2101Beneficial owner
 		 9,000  HKD  3.1000  3.1000   
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position44,727,2563.48
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position44,736,2563.48
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2101Beneficial owner
Long position8,796,256
2101Beneficial owner
Long position35,940,000
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
16/01/201907/07/2027HKD0     
Long position
01/04/202122/03/2029HKD0    600,000
Long position
07/12/201607/12/2026  USD0.025  1,000,000
Long position
07/12/201607/12/2026  USD0.050  2,000,000
Long position
25/08/2022   HKD4.660  14,000,000
Long position
25/08/2022   HKD4.660  14,000,000
Long position
06/01/2023   HKD4.900  4,340,000
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
   
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: Box 28: Such shares represent the restricted shares units and share options granted and to be issued to Dr. Yang pursuant to the Pre-IPO RSU Scheme, Pre-IPO Share Option Scheme and Post-IPO Incentive Schemes. Total of 3,237, 580 restricted shares units granted to Dr. Yang on January 16, 2019 were all vested by February 16, 2023. Box 24: 75,000 restricted share units under the Post-IPO RSU Scheme were versted pursuant to the scheme rules.
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 15/05/2023
(dd/mm/yyyy)